Zenas BioPharma, Inc. (NASDAQ:ZBIO) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Zenas BioPharma, Inc. (NASDAQ:ZBIO) has been given an average recommendation of “Moderate Buy” by the eight analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average 1-year target price among brokers that have covered the stock in the last year is $46.2857.

A number of brokerages have recently commented on ZBIO. Citigroup boosted their price objective on shares of Zenas BioPharma from $27.00 to $46.00 and gave the stock a “buy” rating in a research report on Tuesday, October 28th. Jefferies Financial Group reiterated a “buy” rating and issued a $52.00 price target on shares of Zenas BioPharma in a research note on Monday, October 27th. Evercore ISI initiated coverage on shares of Zenas BioPharma in a research report on Wednesday. They set an “outperform” rating and a $55.00 price target on the stock. Wall Street Zen upgraded Zenas BioPharma from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Zenas BioPharma in a research report on Thursday, October 30th.

Zenas BioPharma Stock Up 1.7%

Shares of Zenas BioPharma stock opened at $40.53 on Friday. The firm has a market cap of $2.18 billion, a PE ratio of -5.73 and a beta of -1.51. The business’s 50 day simple moving average is $28.46 and its 200 day simple moving average is $18.76. The company has a debt-to-equity ratio of 0.37, a quick ratio of 5.66 and a current ratio of 5.66. Zenas BioPharma has a 52-week low of $5.83 and a 52-week high of $41.00.

Zenas BioPharma (NASDAQ:ZBIO) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($1.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.35).

Insider Transactions at Zenas BioPharma

In related news, major shareholder Sr One Capital Management, Llc acquired 126,315 shares of the business’s stock in a transaction dated Thursday, October 9th. The stock was bought at an average price of $19.00 per share, with a total value of $2,399,985.00. Following the acquisition, the insider owned 1,917,895 shares in the company, valued at $36,440,005. This represents a 7.05% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Hongbo Lu bought 263,160 shares of the firm’s stock in a transaction that occurred on Tuesday, October 7th. The stock was purchased at an average cost of $19.00 per share, with a total value of $5,000,040.00. Following the completion of the purchase, the director directly owned 321,983 shares of the company’s stock, valued at $6,117,677. This represents a 447.38% increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders purchased 923,035 shares of company stock valued at $17,628,163. 16.50% of the stock is owned by insiders.

Institutional Trading of Zenas BioPharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in ZBIO. Quarry LP grew its position in shares of Zenas BioPharma by 34.5% in the 3rd quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after acquiring an additional 291 shares during the period. Russell Investments Group Ltd. acquired a new stake in Zenas BioPharma in the 3rd quarter valued at about $30,000. New York State Common Retirement Fund bought a new position in Zenas BioPharma during the first quarter worth about $49,000. BNP Paribas Financial Markets grew its holdings in Zenas BioPharma by 120.0% during the third quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock worth $70,000 after purchasing an additional 1,716 shares during the period. Finally, PNC Financial Services Group Inc. increased its position in Zenas BioPharma by 41.2% during the second quarter. PNC Financial Services Group Inc. now owns 9,179 shares of the company’s stock worth $89,000 after buying an additional 2,679 shares during the last quarter.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.